Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The brokerage currently has a $1.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 19.05% from the company’s previous close.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
A number of other research analysts also recently weighed in on the stock. ValuEngine downgraded shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.
Shares of Bellerophon Therapeutics (NASDAQ BLPH) traded up 1.94% during midday trading on Friday, reaching $1.05. 508,102 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.23. Bellerophon Therapeutics has a 12 month low of $0.43 and a 12 month high of $1.69. The firm’s market cap is $37.29 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. Equities research analysts predict that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in shares of Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 238,300 shares during the period. Susquehanna International Group LLP bought a new position in shares of Bellerophon Therapeutics during the 2nd quarter valued at approximately $1,316,000. Vanguard Group Inc. grew its position in shares of Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after acquiring an additional 211,111 shares during the period. Finally, Goldman Sachs Group Inc. bought a new position in shares of Bellerophon Therapeutics during the 1st quarter valued at approximately $125,000. 45.85% of the stock is owned by hedge funds and other institutional investors.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.